Katarina Fink

Publikationer
Forskningsbidrag
Populärvetenskap och samverkan

Artiklar

Article: ANNALS OF NEUROLOGY. 2024;96(4):678-693
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Piehl F; Alping P; Virtanen S; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Mellergard J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Frisell T
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(8):e16331
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Wang Y; Salzer J; Lycke J; Fink K; Frisell T; Al Nimer F; Svenningsson A
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(5):e16253
Incidence rate and prevalence of pediatric-onset multiple sclerosis in Sweden: A population-based register study
Sandesjo F; Tremlett H; Fink K; Marrie RA; Zhu F; Wickstrom R; McKay KA
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(5):e16228
Rituximab treatment in pediatric-onset multiple sclerosis
Breu M; Sandesjo F; Milos R-I; Svoboda J; Salzer J; Schneider L; Reichelt JB; Bertolini A; Blaschek A; Fink K; Hoeftberger R; Lycke J; Rostasy K; Seidl R; Siegert S; Wickstrom R; Kornek B
Journal article: NEUROLOGY. 2024;102(17_supplement_1)
Granulocyte Activation and Astrocyte Damage Markers in CSF Differentiate Acute NMOSD and MOGAD from MS (P9-14.004)
Leppert D; Watanabe M; Schaedelin S; Piehl F; Fink K; Furlan R; Gastaldi M; Benkert P; Maleska A; Willemse E; Oechtering J; Orleth A; Meier S; Anthony D; Kuhle J
Article: MULTIPLE SCLEROSIS JOURNAL. 2024;30(3):419-431
Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden
Teni FS; Machado A; Fink K; Gyllensten H; Hillert J; Friberg E
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2024;95(2):134-141
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
Longinetti E; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould AM; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Piehl F; Frisell T
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2023;94(9):726-737
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
Leppert D; Watanabe M; Schaedelin S; Piehl F; Furlan R; Gastaldi M; Lambert J; Evertsson B; Fink K; Matsushita T; Masaki K; Isobe N; Kira J-I; Benkert P; Maceski A; Willemse E; Oechtering J; Orleth A; Meier S; Kuhle J
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2023;30(7):1843-1853
Self-reported restrictions in different life domains and associated factors among people with multiple sclerosis in Sweden
Teni FS; Machado A; Murley C; Fink K; Gyllensten H; Dervish J; Hillert J; Friberg E
Article: MULTIPLE SCLEROSIS JOURNAL. 2023;29(6):731-740
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Fink K; Gorczyca A; Alping P; Englund S; Farmand S; Langer-Gould AM; Piehl F; McKay K; Frisell T; Razaz N
Article: JOURNAL OF NEUROIMAGING. 2023;33(2):247-255
MRI detection of brain gadolinium retention in multiple sclerosis: Magnetization transfer vs. T1-weighted imaging
Cananau C; Forslin Y; Bergendal A; Sjostrom H; Fink K; Ouellette R; Wiberg MK; Fredrikson S; Granberg T
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023;70:104481
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
Englund S; Kierkegaard M; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Longinetti E; Frisell T; Piehl F
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023;69:104456
Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1241199
Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay
Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2022;68:104220
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergard J; Nilsson P; Sundstrom P; Svenningsson A; Johansson H; Andersen O
Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2022;9(9):1449-1458
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
Longinetti E; Bower H; McKay KA; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Piehl F; Frisell T
Article: LANCET NEUROLOGY. 2022;21(8):693-703
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Al Nimer F; Sundstrom P; Gunnarsson M; Johansson R; Mellergard J; Rosenstein I; Ayad A; Sjoblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Article: PAEDIATRIC AND PERINATAL EPIDEMIOLOGY. 2022;36(4):577-587
Time of delivery among low-risk women at 37-42 weeks of gestation and risks of stillbirth and infant mortality, and long-term neurological morbidity
Razaz N; Muraca GM; Fink K; Boutin A; John S; Lisonkova S; Stephansson O; Cnattingius S; Joseph KS
Article: SCIENCE ADVANCES. 2022;8(17):eabn1823
Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis
Bronge M; Hogelin KA; Thomas OG; Ruhrmann S; Carvalho-Queiroz C; Nilsson OB; Kaiser A; Zeitelhofer M; Holmgren E; Linnerbauer M; Adzemovic MZ; Hellstrom C; Jelcic I; Liu H; Nilsson P; Hillert J; Brundin L; Fink K; Kockum I; Tengvall K; Martin R; Tegel H; Graslund T; Al Nimer F; Guerreiro-Cacais AO; Khademi M; Gafvelin G; Olsson T; Gronlund H
Article: ANNALS OF NEUROLOGY. 2022;91(3):417-423
Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
McKay KA; Bedri SK; Manouchehrinia A; Stawiarz L; Olsson T; Hillert J; Fink K
Article: MULTIPLE SCLEROSIS JOURNAL. 2021;27(8):1240-1249
Accurate classification of secondary progression in multiple sclerosis using a decision tree
Ramanujam R; Zhu F; Fink K; Karrenbauer VD; Lorscheider J; Benkert P; Kingwell E; Tremlett H; Hillert J; Manouchehrinia A
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:666114
False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases
Kharlamova N; Dunn N; Bedri SK; Jerling S; Almgren M; Faustini F; Gunnarsson I; Ronnelid J; Pullerits R; Gjertsson I; Lundberg K; Manberg A; Pin E; Nilsson P; Hober S; Fink K; Fogdell-Hahn A
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2020;7(6):e903
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2020;46:102519
Employment status of people with multiple sclerosis in relation to 10-year changes in functioning and perceived impact of the disease
Conradsson DM; Forslin M; Fink K; Johansson U; von Koch L; Johansson S
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2020;7(4):e734
Rituximab, MS, and pregnancy
Smith JB; Hellwig K; Fink K; Lyell DJ; Piehl F; Langer-Gould A
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: JOURNAL OF NEUROIMAGING. 2020;30(2):198-204
MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis
Platten M; Martola J; Fink K; Ouellette R; Piehl F; Granberg T
Article: JAMA NEUROLOGY. 2020;77(2):184-191
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2020;37:101468
Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
Juto A; Fink K; Al Nimer F; Piehl F
Article: EUROPEAN RADIOLOGY. 2019;29(3):1355-1364
Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis
Guo C; Ferreira D; Fink K; Westman E; Granberg T
Article: EPIDEMIOLOGY. 2019;30(2):230-233
Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations
Alping P; Piehl F; Langer-Gould A; Frisell T; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Kockum I; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Virtanen S; Vrethem M
Article: PLOS ONE. 2019;14(5):e0217208
Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment
Bedri SK; Nilsson OB; Fink K; Manberg A; Hamsten C; Ayoglu B; Manouchehrinia A; Nilsson P; Olsson T; Hillert J; Gronlund H; Glaser A
Article: MULTIPLE SCLEROSIS JOURNAL. 2018;24(9):1224-1233
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Article: ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION. 2018;99(8):1483-1490
Predictors for Employment Status in People With Multiple Sclerosis: A 10-Year Longitudinal Observational Study
Forslin M; Fink K; Hammar U; von Koch L; Johansson S
Article: JOURNAL OF CLINICAL NEUROLOGY. 2018;14(3):339-344
Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka
Gamage SMK; Wijeweera I; Wijesinghe P; Adikari SB; Fink K; Sominanda HMA
Article: THE LANCET. 2018;391(10127):1263-1273
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallstroem E; Dahlke F
Article: CLINICAL IMMUNOLOGY. 2018;187:15-25
Multiple sclerosis treatment effects on plasma cytokine receptor levels
Bedri SK; Fink K; Manouchehrinia A; Lundstrom W; Kockum I; Olsson T; Hillert J; Glaser A
Article: MULTIPLE SCLEROSIS INTERNATIONAL. 2018;2018:5342936-10
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
Gamage SMK; Wijeweera I; Adikari SB; Fink K; Hillert J; Fogdell-Hahn A; Sominanda HMA
Article: VIRAL IMMUNOLOGY. 2017;30(8):590-600
Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls
Lind A; Freyhult E; Ramelius A; Olsson T; Arnheim-Dahlstroem L; Lamb F; Khademi M; Ambati A; Maeurer M; Bomfim IL; Fink K; Fex M; Torn C; Elding Larsson H; Lernmark A
Article: GENES AND IMMUNITY. 2017;18(2):75-81
The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction
Bomfim IL; Lamb F; Fink K; Szakacs A; Silveira A; Franzen L; Azhary V; Maeurer M; Feltelius N; Darinw N; Hallbook T; Arnheim-Dahlstrom L; Kockum I; Olsson T
Article: NEURODEGENERATIVE DISEASE MANAGEMENT. 2016;6(6s):23-25
Multiple sclerosis e-registries.
Fink K
Article: NEUROLOGY. 2016;87(20):2074-2081
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Salzer J; Svenningsson R; Alping P; Novakova L; Bjorck A; Fink K; Islam-Jakobsson P; Malmestrm C; Axelsson M; Vagberg M; Sundstrom P; Lycke J; Piehl F; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2016;22(8):1071-1079
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
Westerlind H; Stawiarz L; Fink K; Hillert J; Manouchehrinia A
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Lycke J; Svenningsson A; Piehl F
Article: PLOS ONE. 2016;11(4):e0154296
No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination
Lamb F; Ploner A; Fink K; Maeurer M; Bergman P; Piehl F; Weibel D; Sparen P; Arnheim-Dahlstrom L
Article: JOURNAL OF INTERNAL MEDICINE. 2015;278(3):264-276
Increased -haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases
Ambati A; Poiret T; Svahn B-M; Valentini D; Khademi M; Kockum I; Lima I; Arnheim-Dahlstrom L; Lamb F; Fink K; Meng Q; Kumar A; Rane L; Olsson T; Maeurer M
Article: ANNALS OF NEUROLOGY. 2015;77(3):447-457
Lipid-Specific Immunoglobulin M Bands in Cerebrospinal Fluid Are Associated with a Reduced Risk of Developing Progressive Multifocal Leukoencephalopathy during Treatment with Natalizumab
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simo-Castello M; Garcia-Sanchez MI; Lauda F; Llufriu S; Alvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andres C; Tintore M; Ramio-Torrenta L; Rodriguez-Martin E; Picon C; Comabella M; Quintana E; Agueera E; Diaz S; Fernandez-Bolanos R; Garcia-Merino JA; Landete L; Menendez-Gonzalez M; Navarro L; Perez D; Sanchez-Lopez F; Serrano-Castro PJ; Tunon A; Espino M; Muriel A; Bar-Or A; Alvarez-Cermeno JC
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2015;313(1):54-61
Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System
Scheller NM; Svanstrom H; Pasternak B; Arnheim-Dahlstrom L; Sundstrom K; Fink K; Hviid A
Article: JOURNAL OF AUTOIMMUNITY. 2014;50:99-106
A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010
Lind A; Ramelius A; Olsson T; Arnheim-Dahlstrom L; Lamb F; Khademi M; Ambati A; Maeurer M; Nilsson A-L; Bomfim IL; Fink K; Lernmark A
Journal article: NEUROLOGY. 2014;82(10_supplement)
Lipid-Specific IgM Bands Contribute To Stratify PML Risk in MS Patients Treated With Natalizumab (P2.245)
Villar L; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret Ferrer F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Alvarez-Lafuente R; Olascoaga J; Olaskoaga Urtaza J; Oterino A; Llufriu Duran S; Lauda F; De Andres C; Garcia-Merino JA; Fernandez-Bolaños R; Landete Pascual L; Aguera Morales E; Diaz Nicolas S; Menendez M; Navarro L; Perez D; Ramio L; Sanchez Lopez F; Serrano Castro P; Tuñon A; Alvarez-Cermeño J
Journal article: NEUROLOGY. 2014;82(10_supplement)
HLA Genes and Interferon-beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis (P1.213)
Fink K; Link J; Lundkvist M; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
Article: MULTIPLE SCLEROSIS JOURNAL. 2014;20(4):445-450
Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a
Hedstrom AK; Ryner M; Fink K; Fogdell-Hahn A; Alfredsson L; Olsson T; Hillert J
Article: JOURNAL OF PEDIATRIC SURGERY. 2014;49(4):622-625
A novel stop mutation in the EDNRB gene in a family with Hirschsprung's disease associated with Multiple Sclerosis
Granstrom AL; Markljung E; Fink K; Nordenskjold E; Nilsson D; Wester T; Nordenskjold A
Article: PLOS ONE. 2014;9(3):e90479
Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
Link J; Ryner ML; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
Article: NEUROBIOLOGY OF DISEASE. 2007;25(1):1-7
Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas
Hellweg R; Zueger M; Fink K; Hoertnagl H; Gass P
Visa fler

Alla övriga publikationer

Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:968-969
CLADCOMS- CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
Larsson V; Nilsson P; Magdalena LA; Svenningsson A; Gunnarsson M; Ayad A; Vrethem M; Burman J; Lycke J; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:855-856
Evaluating the impact of gadolinium on clinical T1 brain MRI volumetrics in Multiple Sclerosis
Cananau C; Ouellette R; Fink K; Granberg T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:180-181
Maternal and infant infections following treatment with rituximab or natalizumab prior to or during pregnancy
Gorczyca A; Razaz N; Piehl F; Frisell T; Fink K
Editorial comment: OBSTETRICAL AND GYNECOLOGICAL SURVEY. 2023;78(1):1-2
Time of Delivery Among Low-Risk Women at 37-42 Weeks of Gestation and Risks of Stillbirth and Infant Mortality, and Long-term Neurological Morbidity
Razaz N; Muraca GM; Fink K; Boutin A; John S; Lisonkova S; Stephansson O; Cnattingius S; Joseph KS
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:358-359
Hypogammaglobulinemia during rituximab treatment in multiple sclerosis - the Hypogamma-MS study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Salzer J; Lycke J; Fink K; Wang Y; Frisell T; Al Nimer F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:617-618
Prediction of gammaglobulin decrease during rituximab treatment in MS
Kallin S; Hallberg S; Evertsson B; Wang Y; Fink K; Salzer J; Lycke J; Al Nimer F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):847-848
CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
Fink K; Nilsson P; Alonso L; Sveningsson A; Gunnarsson M; Lange N; Ayad A; Vrethem M; Burman J; Lycke J; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):515-516
SARS-COV2 exposure rates and serological response of people living with MS
Longinetti E; Hogelin KA; Kockum I; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Nilsson P; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Frisell T; Olsson T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):189-190
Aspects of life with focus on family planning and pregnancy among women with MS
Fink K; Gorczyca A; Pettersson E; Hillert J; Friberg E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):95-96
Primary analysis of ProTEct-MS, a randomised, placebocontrolled, phase 2 study of temelimab for the prevention of neurodegenerationin rituximab-treated patients with relapsing multiple sclerosis
Piehl F; Cree BA; Granberg T; Granziera C; Al Nimer F; Andersson M; Barakovic M; Fink K; Ouelette R; Sandberg E; Kuhle J; Wojcik J; Berthuy N; Medina J; Kremer D; Kuery P; Leppert D
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):672-673
Trajectories of disease-modifying therapies and associated sickness absence and disability pension among people with multiple sclerosis
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):200-201
Limitations in different life domains early in the disease course among people with multiple sclerosis in Sweden
Teni FS; Machado A; Murley C; Fink K; Gyllensten H; Dervish J; Hillert J; Friberg E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):763-764
Genetic variation in GLA elucidates a link between Fabry Disease and Multiple Sclerosis in Sweden
Stridh P; Shchetynsky K; James T; Kockum I; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):358
Rituximab in paediatric onset multiple sclerosis - a european multicenter experience
Sandesjo F; Breu M; Reichelt JB; Blaschek A; Lycke J; Svoboda J; Salzer J; Fink K; Rostasy K; Bertolini A; Seidl R; Hoftberger R; Milos R-I; Kornek B; Wickstrom R
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):245-246
Hypogammaglobulinemia during and after pregnancy in women with MS treated with rituximab prior to conception
Iliopoulou VA; Cucuzza CS; Gorczyca A; Manouchehrinia A; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):577
Comparative effectiveness, safety, and immunogenicity of Rituximab biosimilars (Truxima/Ritemvia and Rixathon) to their originator (Mabthera) in multiple sclerosis
Dunn N; Manouchehrinia A; Kharlamova N; Querejazu MO; Alexopoulos H; Bedri SK; Englund S; Fink K; Fogdell-Hahn A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):408-409
Detecting brain gadolinium retention in MS with MRI: a comparison of 2D Spin Echo, 3D gradient echo, quantitative susceptibility mapping and magnetization transfer
Cananau C; Forslin Y; Sjostrom H; Bergendal A; Fink K; Wiberg MK; Ouellette R; Fredrikson S; Granberg T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):106
Multiple sclerosis and risks for adverse perinatal and pregnancy outcomes: Results from a nationwide cohort study
Fink K; Gorczyca A; Alping P; Langer-Gould AM; Cnattingius S; Frisell T; Piehl F; Razaz N
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):634-635
Rituximab treatment prior to pregnancy in women with multiple sclerosis - perinatal outcomes in Swedish cohort
Gorczyca A; Alping P; Frisell T; Razaz N; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):308
A cost-minimization analysis shows significant resource savings associated with the introduction of natalizumab by subcutaneous injection in Sweden, from a socio-economic perspective
Gianinazzi M; Soderbarg K; Jomaa K; Ralph L; Davison N; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):21-22
Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab
Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Vrethem M; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):344-345
T cell reactivity screening reveals four novel CNS autoantigens in multiple sclerosis
Bronge M; Asplund Hogelin K; Thomas OG; Ruhrmann S; Carvalho-Querioz C; Nilsson O; Kaiser A; Holmgren E; Linnerbauer M; Adzemovic MZ; Zeitelhofer M; Hellstrom C; Jelcic I; Liu H; Nilsson P; Hillert J; Brundin L; Fink K; Martin R; Tegel H; Graslund T; Al Nimer F; Guerreiro-Cacais AO; Khademi M; Gafvelin G; Olsson T; Gronlund H
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):257
Cognitive change in the pre- and post-relapse period: Evidence from a nationwide longitudinal cohort study
Mckay KA; Bedri SK; Manouchehrinia A; Stawiarz L; Olsson T; Hillert J; Fink K
Preprint: MEDRXIV. 2020
SARS-CoV-2 serological tests can generate false positive results for samples from patients with chronic inflammatory diseases
Kharlamova N; Dunn N; Bedri SK; Jerling S; Almgren M; Faustini F; Gunnarsson I; Rönnelid J; Pullerits R; Gjertsson I; Lundberg K; Månberg A; Pin E; Nilsson P; Hober S; Fink K; Fogdell-Hahn A
Preprint: MEDRXIV. 2020
Accurate classification of secondary progression in multiple sclerosis
Ramanujam R; Zhu F; Fink K; Danylaitė Karrenbauer V; Lorscheider J; Benkert P; Kingwell E; Tremlett H; Hillert J; Manouchehrinia A; The BeAMS Study group
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:397
Perinatal outcomes in women with multiple sclerosis: a population based cohort study in Sweden
Razaz N; Piehl F; Cnattingius S; Frisell T; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:396-397
Disease activity in women with multiple sclerosis treated with rituximab and natalizumab
Razaz N; Piehl F; McKay KA; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:173-174
Rituximab, multiple sclerosis and pregnancy
Fink K; Gorczyca A; Smith J; Piehl F; Langer-Gould A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:290-291
Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; No evidence of rebound disease activity
Juto A; Fink K; Al Nimer F; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:551-552
Effect of extended interval dosing of natalizumab on patients' perceived disease activity, information processing speed and physical disability
Fink K; Manouchehrinia A; Olsson T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:542-543
Longitudinal follow up to determine the clinical relevance of anti-drug antibodies against Rituximab in multiple sclerosis
Dunn N; Manouchehrinia A; Englund S; Juto A; Kharlamova N; Fink K; Piehl F; Fogdell-Hahn A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:686
Low dose rituximab depletes B cells and lowers IgM in blood in MS patients: a study on possible biomarkers to predict treatment response and adverse event profile
Evertsson B; Fink K; Finn A; Piehl F; Nimer F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:146-147
Disease-modifying therapies for multiple sclerosis in association with pregnancy: a Swedish nation-wide cohort study
Gorczyca A; Alping P; Frisell T; Piehl F; Langer-Gould A; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:209
Precision of manual vs. automated corpus callosum atrophy measurements in multiple sclerosis
Platten M; Martola J; Fink K; Granberg T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:714
Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location
Alping P; Burman J; Fink K; Gunnarsson M; Lycke J; Nilsson P; Salzer J; Vrethem M; Langer-Gould A; Svenningsson A; Frisell T; Piehl F
Letter: MULTIPLE SCLEROSIS JOURNAL. 2017;23(2):305-307
Re: Declines in the diagnosis of primary progressive MS-A critical change in phenotype or critical measurement error?
Westerlind H; Stawiarz L; Fink K; Hillert J; Manouchehrinia A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):342-343
Rituximab in multiple sclerosis; frequency and clinical relevance of anti-drug antibodies
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:348-349
Rituximab in multiple sclerosis, frequency and clinical relevance of anti-rituximab drug antibodies
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:299-300
MS treatment effects on plasma cytokine receptor levels
Bedri SK; Fink K; Manouchehrinia A; Lundstrom W; Kockum I; Olsson T; Hillert J; Glaser A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:134-135
Neonatal and delivery outcomes of babies to mothers with multiple sclerosis in Sweden
Fink K; Manouchehrinia A; Glaser A; Hillert J
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):293
MS treatment effects on plasma cytokine receptor levels
Bedri SK; Fink K; Manouchehrinia A; Lundstrom W; Kockum I; Olsson T; Hillert J; Glaser A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:819-820
A randomized, multi-center, open-label, observational study to investigate quality of life improvement in patients with relapse remitting multiple sclerosis on first-line treatment that are using a wearable device with biofeedback for stress
Fink K; Klappe U; Lindblom S
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:426-427
A 10-year study of predictors for employment status in people with multiple sclerosis
Forslin M; von Koch L; Fink K; Johansson S
Conference publication: JOURNAL OF SLEEP RESEARCH. 2016;25:285
Sleep education in neurology (SEN) - preliminary Results of a European survey
Sieminski M; Pizza F; Rakusa M; Gak S; Hidalgo H; Schreier D; Muntean L; Fink K; Pijpers A; Fronczek R; Karamyan A; Cochen V; Rupprecht S; Sonka K; Khachatryan S; Falup-Pecurariu C; Diaconu S; Kallweit U
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:431
Applying the revised clinical course definitions to describe the phenotype of patients from the Swedish multiple sclerosis register
Mentesidou E; Manouchehrinia A; Fink K; Hillert J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:49
Rituximab in multiple sclerosis; data from the swedish MS registry.
Alping P; Svenningsson A; Salzer J; Burman J; Dahle C; Fink K; Hillert J; Lycke J; Landtblom A-M; Martin C; Nilsson P; Walentin F; Olsson T; Frisell T; Piehl F
Letter: PSYCHIATRY AND CLINICAL NEUROSCIENCES. 2015;69(2):124-125
Successful treatment of excessive supragastric belching by combination of pregabalin and baclofen
Kunte H; Kronenberg G; Fink K; Harms L; Hellweg R
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:574
Rituximab in multiple sclerosis, a long term safety and efficacy study
Islam-Jakobsson P; Alping P; Salzer J; Bjorck A; Fink K; Frisell T; Piehl F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:555
Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology
Alping P; Islam-Jakobsson P; Novakova L; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Frisell T; Lycke J; Svenningsson A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:725-726
Does multiple sclerosis influence women's fertility?
Fink K; Tinghog P; Wiberg M; Glaser A; Alexandersson K; Hillert J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:352-353
From genetic variations to plasma cytokine receptor levels during MS treatment
Bedri SK; Fink K; Lundstrom W; Olsson T; Glaser A; Hillert J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:56
A significant decrease in the diagnosis of primary progressive multiple sclerosis: a cohort study
Westerlind H; Stawiarz L; Fink K; Hillert J; Manouchehrinia A
Meeting abstract: JOURNAL OF NEUROIMMUNOLOGY. 2014;275(1-2):50-51
Genetic study of Pandemrix-associated narcolepsy
Bomfim IL; Fink K; Lamb F; Darin N; Szakacs A; Hallbook T; Piehl F; Dahlstrom LA; Kockum I; Olsson T
Conference publication: JOURNAL OF NEUROLOGY. 2014;260:S262
Predictors of disability extremes in patients with multiple sclerosis treated with interferon-beta using the Swedish multiple sclerosis registry
Fink K; Glaser A; Fogdell-Hahn A; Hillert J
Conference publication: JOURNAL OF NEUROLOGY. 2014;261:S284
Progressive multifocal leukoencephalopathy in a patient with adrenal cortical tumor
Fink K; Samuelsson K; Green B; Zachau A; Lilja A
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2014;21:427
Progressive multifocal leukoencephalopathy in a patient with adrenal cortical tumor
Fink K; Samuelsson K; Green B; Zachau A; Lilja A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;79(6):477
From Genetic Variations to Biomarkers
Bedri SK; Bronge M; Fink K; Lundstrom W; Glaser A; Gronlund H; Hillert J
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;79(6):450
Human Leucocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Antidrug Antibodies in Multiple Sclerosis
Ryner ML; Link J; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
Conference publication: HLA. 2014;84(1):109
HUMAN LEUKOCYTE ANTIGEN GENES AND INTERFERON BETA PREPARATIONS INFLUENCE RISK OF DEVELOPING NEUTRALIZING ANTI-DRUG ANTIBODIES IN MULTIPLE SCLEROSIS
Link J; Ryner ML; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2013;19(11):56-57
Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab
Villar L; Costa-Frossard L; Fernandez O; Montalban X; Casanova B; Izquierdo G; Masterman T; Coret F; Tumani H; Saiz A; Arroyo R; Leyva L; Espejo C; Garcia-Sanchez MI; Fink K; Lauda F; Llufriu S; Alvarez-Lafuente R; Olascoaga J; Oterino A; De Andres C; Garcia-Merino JA; Landete L; Menendez M; Navarro L; Perez D; Ramio L; Tunon A; Alvarez-Cermeno JC
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2013;19(11):516
Smoking and risk of treatment-induced neutralizing antibodies to interferon β 1a
Hedstrom AK; Ryner M; Fink K; Fogdell-Hahn A; Alfredsson L; Olsson T; Hillert J
Conference publication: NEUROLOGY. 2012;78:p05.121
Investigation of the Effect of Human Leukocyte Antigen on the Development of Neutralizing Antibodies in Interferon-beta Treated Patients with Multiple Sclerosis (*The First Three Authors Contributed Equally to This Work)
Fink K; Lundkvist M; Link J; Kockum I; Hermanrud C; Brynedal B; Hillert J; Fogdell-Hahn A
Conference publication: IMMUNOLOGY. 2012;137:663
Effect of HLA genotype on the development of neutralizing antibodies to interferon beta in patients with multiple sclerosis
Lundkvist M; Link J; Fink K; Hermanrud C; Brynedal B; Fogdell-Hahn A; Kockum I; Hillert J
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2012;19:361
Preparation-specific genetically determined risk of developing neutralizing antibodies towards interferon-beta in patients with multiple sclerosis
Link J; Fink K; Lundkvist M; Brynedal B; Kockum I; Fogdell-Hahn A; Hillert J
Conference publication: JOURNAL OF NEUROLOGY. 2012;259:S149
HLA-DRB1*15 and HLA-A*02 are associated with higher risk of developing neutralising antibodies and clinically relevant titres against interferon-beta in multiple sclerosis
Link J; Lundkvist M; Fink K; Hermanrud C; Brynedal B; Fogdell-Hahn A; Kockum I; Hillert J
Conference publication: JOURNAL OF NEUROLOGY. 2011;258:264
How do patients with neutralising antibodies to recombinant interferon-β treatment develop in their clinical outcome?
Fink K; Westerlind H; Lundkvist M; Fogdell-Hahn A; Hillert J
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2011;73(4):369-370
Clinical Outcomes in Patients with Multiple Sclerosis who Develop Neutralizing Antibodies to Recombinant Interferon-Beta Treatment
Fink K; Westerlind H; Lundkvist M; Fogdell-Hahn A; Hillert J
Visa fler

Forskningsbidrag

Multiple sclerosis, pregnancy and treatment with rituximab
Swedish Research Council
1 January 2024 - 31 December 2026
Uncovering sustainable work strategies for individuals with Multiple Sclerosis
Swedish Research Council for Health Working Life and Welfare
1 January 2024 - 31 December 2026
RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. A randomized trial of long-term dosage of rituximab in multiple sclerosis
Swedish Research Council
1 December 2020 - 31 December 2024

Artiklar

Alla övriga publikationer

Forskningsbidrag

Nyheter från KI

Kalenderhändelser från KI